X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

LANCET ONCOLOGY

期刊標題檢索 LANCET ONCOL 最新評論: The basic article is being received. (2024-07-16)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[LANCET ONCOLOGY]您好,您是該頁面的第 65390 位訪客。

期刊簡介
期刊名稱LANCET ONCOLOGY LANCET ONCOLOGY
LetPub Score
9.8
50 ratings
Rate

Reputation
10.0

Influence
9.7

Speed
9.3

期刊簡稱LANCET ONCOL
ISSN1470-2045
E-ISSN1474-5488
h-index274
CiteScore
CiteScoreSJRSNIPCiteScore Rank
62.1012.17910.538
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q15 / 404

自引率 (2023-2024)1.20%自引率趨勢
掲載範囲
The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Manuscripts must be solely the work of the author(s) stated, must not have been previously published elsewhere, and must not be under consideration by another journal. All papers should be written to be clearly understandable to the journal’s readers in a wide range of specialties and countries.
官方網站http://www.thelancet.com/journals/lanonc/issue/current
在線稿件提交https://www.editorialmanager.com/THELANCETONCOLOGY
開放訪問No
出版商Lancet Publishing Group
主題領域医学
出版國/地區UNITED STATES
發行頻率月刊
創刊年2000
每年文章數126每年文章數趨勢
黃金OA百分比18.31%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ17/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1470-2045%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Ordinary, 3-8 Week(s)
競爭力 *來自作者的數據: Extremely difficult
參考鏈接
相關期刊 【LANCET ONCOLOGY】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    ANNALS OF ONCOLOGYH-index: 210

    CiteScore: 63.90
    CANCER CELLH-index: 295

    CiteScore: 55.20
    JOURNAL OF CLINICAL ONCOLOGYH-index: 494

    CiteScore: 41.20
    CANCER RESEARCHH-index: 411

    CiteScore: 16.10
    SEMINARS IN CANCER BIOLOGYH-index: 134

    CiteScore: 26.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHH-index: 67

    CiteScore: 18.20
    CLINICAL CANCER RESEARCHH-index: 292

    CiteScore: 20.10
    學科內最受檢索的期刊 頁面查看次數
    CANCER LETTERS331025
    CANCER RESEARCH312135
    BMC CANCER245514
    Asian Pacific Journal of Cancer Prevention219247
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH198016
    INTERNATIONAL JOURNAL OF CANCER191631
    CLINICAL CANCER RESEARCH181667
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY176443
    ONCOLOGY REPORTS175032
    CA-A CANCER JOURNAL FOR CLINICIANS163632
  •  

    LANCET ONCOLOGY LANCET ONCOLOGY
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [LANCET ONCOLOGY] 的評論撰寫評論
作者: Adelaide Lawson


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-16 08:42:36 評論於
The basic article is being received.
(0) 讚! | Adelaide Lawson

作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-19 20:32:31 評論於
Review speed: 3.0 | Submission hit rate: 5.0 Emphasis on research directions: tumors; tumor immunotherapy; solid tumor experience sharing: The impact factor for the year 2023 is 41.6, which is still good overall and still in a leading position in the field of oncology. CA-A CANCER JOURNAL FOR CLINICIANS, 503.1, dominates with one article, without considering Nature Reviews Clinical Oncology 81.3, mainly publishes reviews. ANNALS OF ONCOLOGY, 56.7, mainly reviews. CANCER CELL 48.8, mainly focuses on translational medicine, and starting from the past two years, also publishes some clinical trial articles. JOURNAL OF CLINICAL ONCOLOGY, 42.1, is similar to LANCET ONCOLOGY, ranking equally. Moving down, Cancer Discovery, 29.7, also publishes articles on basic research and translational medicine, which are further from clinical practice. Journal of Hematology & Oncology 29.5 is a comprehensive journal for hematologic tumors and solid tumors. Molecular Cancer 27.7 is also related to tumor translational medicine.
(0) 讚! | 是志丹吖

作者: 北国迎荷


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-06-08 09:31:42 評論於
Please translate the following passage into English: 8
(0) 讚! | 北国迎荷

作者: 混元新曦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-18 22:18:18 評論於
Haha, the road of scientific research is long in life
(0) 讚! | 混元新曦

作者: 混元新曦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-18 09:23:18 評論於
The Lancet journal is fine as long as the article is good. If the journal invites submissions, it can still be accepted
(0) 讚! | 混元新曦

作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-28 22:03:56 評論於
Impact factor of 51.1, top journal
(0) 讚! | 是志丹吖

作者: 擒龙小谷


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-26 15:17:57 評論於
Submitting articles every day, worrying every day
(0) 讚! | 擒龙小谷

作者: 坠星倩影


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-03 13:36:31 評論於
It's best
(0) 讚! | 坠星倩影

作者: 两仪景胜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-06 18:28:21 評論於
Looking forward, multicenter is the mainstream, everything else is outdated
(0) 讚! | 两仪景胜

作者: 一二三四我是小雨点点


領域: 医学
審稿時間: 1.0 month(s)
結果: 拒稿


撰寫評論

2022-03-30 22:03:13 評論於
The editor was very nice, although my submission was ultimately rejected. However, the rejection letter was sincere and included substantive feedback specific to my article. In the end, they recommended another journal and suggested transferring my submission there.
(0) 讚! | 一二三四我是小雨点点

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-02-10 19:47:52 評論於
Unless it is a super large sample
(0) 讚! | 法慧和同

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 21:19:53 評論於
2 weeks to 3 months
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 14:07:37 評論於
The review process may be taking longer than expected, and it has not been completed yet
(0) 讚! | 维尔娜菲茨杰拉德

作者: 深渊兴业


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 17:43:23 評論於
Why haven't I heard back after a month of applying?
(0) 讚! | 深渊兴业

作者: 北国博达


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 23:10:31 評論於
How long does it usually take for a journal to review a manuscript?
(0) 讚! | 北国博达

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-09-11 21:09:18 評論於
Of course
(0) 讚! | 法慧和同

作者: 法慧和同


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-09-11 16:32:14 評論於
It is best to add some conversion research
(0) 讚! | 法慧和同

作者: 运骏姑娘


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-09-09 09:34:46 評論於
Can a purely clinical research RCT be conducted?
(0) 讚! | 运骏姑娘

作者: 采南小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-09-05 16:26:36 評論於
Very visionary
(0) 讚! | 采南小姐姐

作者: Q-q


領域: 医学
審稿時間: 4.0 month(s)
結果: 待定&不明


撰寫評論

2020-06-26 22:07:04 評論於
It has been more than 4 months since I submitted the manuscript, and there has been no news. Unexpectedly, I was told that no reviewers were found. Is it because of the serious pandemic in Europe and America? SAD!

(41) 讚! | Q-q

作者: 深渊妙芙


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-03-13 23:01:56 評論於
How many people can share one?
(0) 讚! | 深渊妙芙

作者: 太山羽沫


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-11-15 20:23:54 評論於
Are you accepting retrospective cohort studies?
(0) 讚! | 太山羽沫

作者: 中原兴思


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-21 19:19:05 評論於
We only accept transformational research articles, not purely foundational ones
(0) 讚! | 中原兴思

作者: 中原兴思


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-21 09:11:43 評論於
Zhou often publishes this periodical. 153****5167 (no pseudonym) Published on 2017-02-02 Research area: tumors; cancer; SCI (2015): 26.509 SCI (2014): 24.69 is Zhou Caicun
(0) 讚! | 中原兴思

作者: 寂灭巧易


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-01-20 09:34:28 評論於
Classmate, does this magazine submission require an analysis? Especially the author's information, font size and format requirements, I have found them all
(0) 讚! | 寂灭巧易

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [LANCET ONCOLOGY] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*